Inventor · disambiguated record
Eric Poma
Also filed as: POMA ERIC
20 granted patents·31 pending applications·81 citations·filing 2014–2024
93Inventor score
Top patents by PatentIndex Score
51 records- 0197US11857628B2Shiga toxin A subunit effector polypeptides, Shiga toxin effector scaffolds, and cell-targeting molecules for site-specific conjugationMOLECULAR TEMPLATES INC·Filed 2021·Granted Jan 2, 2024·4 cites·22 claims
- 0297US11389542B1Shiga toxin a subunit effector polypeptides, Shiga toxin effector scaffolds, and cell-targeting molecules for site-specific conjugationMOLECULAR TEMPLATES INC·Filed 2021·Granted Jul 19, 2022·5 cites·10 claims
- 0397US11312751B2MHC class I epitope delivering polypeptidesMOLECULAR TEMPLATES INC·Filed 2021·Granted Apr 26, 2022·6 cites·3 claims
- 0496US11225509B2HER2-targeting molecules comprising de-immunized, Shiga toxin A subunit scaffoldsMOLECULAR TEMPLATES INC·Filed 2020·Granted Jan 18, 2022·4 cites·6 claims
- 0595US10815469B2Cell-targeting molecules comprising protease-cleavage resistant, Shiga toxin A subunit effector polypeptides and carboxy-terminal moietiesMOLECULAR TEMPLATES INC·Filed 2015·Granted Oct 27, 2020·22 cites·40 claims
- 0694US11365223B2De-immunized, Shiga toxin a subunit scaffolds and cell-targeting molecules comprising the sameMOLECULAR TEMPLATES INC·Filed 2021·Granted Jun 21, 2022·7 cites·14 claims
- 0794US11136395B2PD-L1 -binding molecules comprising Shiga toxin A subunit scaffoldsMOLECULAR TEMPLATES INC·Filed 2020·Granted Oct 5, 2021·10 cites·30 claims
- 0894US10421958B2Methods of screening, selecting, and identifying cytotoxic recombinant polypeptides based on an interim diminution of ribotoxicityMOLECULAR TEMPLATES INC·Filed 2015·Granted Sep 24, 2019·11 cites·23 claims
- 0993US11406692B2Cell-targeting molecules comprising de-immunized, Shiga toxin a subunit effectors and CD8+ t-cell epitopesMOLECULAR TEMPLATES INC·Filed 2021·Granted Aug 9, 2022·4 cites·15 claims
- 1092US11713347B2CD38-binding proteins comprising de-immunized Shiga toxin A subunit effectorsMILENNIUM PHARMACEUTICALS INC·Filed 2020·Granted Aug 1, 2023·4 cites·18 claims
- 1190US2024409589A1Mhc class i epitope delivering polypeptidesMOLECULAR TEMPLATES INC·Filed 2024·Application pending·0 cites
- 1287US2024360184A1De-immunized shiga toxin a subunit effector polypeptides for applications in mammalsMOLECULAR TEMPLATES INC·Filed 2024·Application pending·0 cites
- 1385US2024082404A1Shiga toxin a subunit effector polypeptides, shiga toxin effector scaffolds, and cell-targeting molecules for site-specific conjugationMOLECULAR TEMPLATES INC·Filed 2023·Application pending·0 cites
- 1482US12037367B2MHC class I epitope delivering polypeptidesMOLECULAR TEMPLATES INC·Filed 2022·Granted Jul 16, 2024·0 cites·11 claims
- 1582US11918649B2PD-L1-binding molecules comprising Shiga toxin a subunit scaffoldsMOLECULAR TEMPLATES INC·Filed 2020·Granted Mar 5, 2024·1 cites·43 claims
- 1677US12180262B2CD38-binding proteins comprising de-immunized Shiga toxin A subunit effectorsMILLENNIUM PHARM INC·Filed 2023·Granted Dec 31, 2024·0 cites·31 claims
- 1776US2023331785A1Her2-targeting molecules comprising de-immunized, shiga toxin a subunit scaffoldsMOLECULAR TEMPLATES INC·Filed 2023·Application pending·0 cites
- 1875US12065469B2De-immunized Shiga toxin a subunit effector polypeptides for applications in mammalsMOLECULAR TEMPLATES INC·Filed 2021·Granted Aug 20, 2024·0 cites·14 claims
- 1972US2024207399A1Pd-l1-binding molecules comprising shiga toxin a subunit scaffoldsMOLECULAR TEMPLATES INC·Filed 2024·Application pending·0 cites
- 2072US2022354938A1Cell-targeting molecules comprising de-immunized, shiga toxin a subunit effectors and cd8+ t-cell epitopesMOLECULAR TEMPLATES INC·Filed 2022·Application pending·0 cites
- 2171US10450354B2CD20-binding immunotoxins for inducing cellular internalization and methods using sameMOLECULAR TEMPLATES INC·Filed 2014·Granted Oct 22, 2019·1 cites·40 claims
- 2270US11142584B2CD20-binding proteins comprising Shiga toxin A subunit effector regions for inducing cellular internalization and methods using sameMOLECULAR TEMPLATES INC·Filed 2015·Granted Oct 12, 2021·1 cites·18 claims
- 2370US11104707B2Multivalent CD20-binding molecules comprising Shiga toxin a subunit effector regions and enriched compositions thereofMOLECULAR TEMPLATES INC·Filed 2019·Granted Aug 31, 2021·0 cites·18 claims
- 2470US2022162271A1Her2-targeting molecules comprising de-immunized, shiga toxin a subunit scaffoldsMOLECULAR TEMPLATES INC·Filed 2021·Application pending·0 cites
- 2569US10392425B2Multivalent CD20-binding molecules comprising Shiga toxin A subunit effector regions and enriched compositions thereofMOLECULAR TEMPLATES INC·Filed 2016·Granted Aug 27, 2019·1 cites·24 claims
- 2668US2022281926A1De-immunized, shiga toxin a subunit scaffolds and cell-targeting molecules comprising the sameMOLECULAR TEMPLATES INC·Filed 2022·Application pending·0 cites
- 2767US2019153044A1MHC Class I Epitope Delivering PolypeptidesMOLECULAR TEMPLATES INC·Filed 2018·Application pending·0 cites
- 2867US2022267384A1Proteins comprising binding regions, shiga toxin a subunit effector regions, and carboxy-terminal, endoplasmic reticulum localization signal motifsMOLECULAR TEMPLATES INC·Filed 2022·Application pending·0 cites
- 2962US2021008208A1Shiga toxin a subunit effector polypeptides, shiga toxin effector scaffolds, and cell-targeting molecules for site-specific conjugationMOLECULAR TEMPLATES INC·Filed 2017·Application pending·0 cites
- 3061US12180284B2Clinical methods for use of a PD-L1-binding molecule comprising a Shiga toxin effectorMOLECULAR TEMPLATES INC·Filed 2021·Granted Dec 31, 2024·0 cites·41 claims
- 3160US2021017512A1Cell-targeting molecules comprising protease-cleavage resistant, shiga toxin a subunit effector polypeptides and carboxy-terminal moietiesMOLECULAR TEMPLATES INC·Filed 2020·Application pending·0 cites
- 3258US11248061B2Multivalent CD20-binding molecule comprising Shiga toxin A subunit effector polypeptides and enriched compositions thereofMOLECULAR TEMPLATES INC·Filed 2016·Granted Feb 15, 2022·0 cites·23 claims
- 3358US2019382755A1Methods of screening, selecting, and identifying cytotoxic recombinant polypeptides based on an interim diminution of ribotoxicityMOLECULAR TEMPLATES INC·Filed 2019·Application pending·0 cites
- 3458US2023357406A1Ctla-4 binding molecules comprising shiga toxin a subunit scaffolds and uses thereofMOLECULAR TEMPLATES INC·Filed 2023·Application pending·0 cites
- 3557US2022401568A1Cell-targeting molecules comprising shiga toxin a subunit effectors and cd8+ t-cell epitopesMOLECULAR TEMPLATES INC·Filed 2021·Application pending·0 cites
- 3657US2022306700A1Pd-l1 binding proteins comprising shiga toxin a subunit scaffolds and cd8+ t cell antigensMOLECULAR TEMPLATES INC·Filed 2022·Application pending·0 cites
- 3757US2020002387A1Cd20-binding immunotoxins for inducing cellular internalization and methods using sameMOLECULAR TEMPLATES INC·Filed 2019·Application pending·0 cites
- 3856US2020024312A1Cell-targeting molecules comprising de-immunized, shiga toxin a subunit effectors and cd8+ t-cell epitopesMOLECULAR TEMPLATES INC·Filed 2018·Application pending·0 cites
- 3956US2016347798A1Mhc class i epitope delivering polypeptides and cell-targeted molecules for direct cell killing and immune stimulation via mhc class i presentation and methods regarding the sameMOLECULAR TEMPLATES INC·Filed 2015·Application pending·0 cites
- 4054US2018258144A1Cytotoxic proteins comprising cell-targeting binding regions and shiga toxin a subunit regions for selective killing of specific cell typesMOLECULAR TEMPLATES INC·Filed 2018·Application pending·0 cites
- 4153US2016340394A1De-immunized shiga toxin a subunit effector polypeptides for applications in mammalsMOLECULAR TEMPLATES INC·Filed 2015·Application pending·0 cites
- 4253US2021324082A1Pd-l1 targeting molecules comprising shiga toxin a subunit scaffoldsMOLECULAR TEMPLATES INC·Filed 2021·Application pending·0 cites
- 4353US2018291359A1Cell-targeting molecules comprising amino-terminus proximal or amino-terminal, shiga toxin a subunit effector regionsMOLECULAR TEMPLATES INC·Filed 2018·Application pending·0 cites
- 4450US2023295342A1Clinical methods for use of her2 binding moleculesPOMA ERIC·Filed 2021·Application pending·0 cites
- 4547US2018258143A1De-Immunized, Shiga Toxin A Subunit Scaffolds and Cell-Targeting Molecules Comprising the SameMOLECULAR TEMPLATES INC·Filed 2016·Application pending·0 cites
- 4647US2016177284A1Cell-targeted molecules comprising amino-terminus proximal or amino-terminal shiga toxin a subunit effector regionsMOLECULAR TEMPLATES INC·Filed 2015·Application pending·0 cites
- 4744US2021155671A1Uses of cd20-binding molecules and additional therapeutic agentsMOLECULAR TEMPLATES INC·Filed 2020·Application pending·0 cites
- 4843US2021138076A2Cell-targeting molecules comprising shiga toxin a subunit effectors and cd8+ t-cell epitopesMOLECULAR TEMPLATES INC·Filed 2016·Application pending·0 cites
- 4940US2017143814A1Immunotherapy using cell-targeting molecules comprising shiga toxin a subunit effectors and cd8+ t-cell epitopesMOLECULAR TEMPLATES INC·Filed 2017·Application pending·0 cites
- 5040US2017002046A1Proteins comprising binding regions, shiga toxin a subunit effector regions, and carboxy-terminal, endoplasmic reticulum localization signal motifsMOLECULAR TEMPLATES INC·Filed 2015·Application pending·0 cites
Showing the top 50 of 51 patent records by PatentIndex Score.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →